BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. today announced that it will participate in the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11th - 14th in San Francisco. Christian Itin, Ph.D., Micromet’s President and CEO, will present a 30 minute corporate overview on Thursday, January 14th at 12:30 PM PST.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) technology, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
Micromet, Inc.
